TD Private Client Wealth’s Sarepta Therapeutics SRPT Stock Holding History

TD Private Client Wealth’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$593	Hold	33	–	–	﹤0.01%	1552
2026 Q1	$718	Sell	33 -41	-55%	-$794	﹤0.01%	1444
2025 Q4	$1.59K	Buy	74 +41	+124%	+$864	﹤0.01%	1301
2025 Q3	$636	Buy	+33	New	+$588	﹤0.01%	1413
2022 Q1	–	Sell	-7	Closed	-$630	–	1326
2021 Q4	$630	Sell	7 -31	-82%	-$2.65K	﹤0.01%	1110
2021 Q3	$3.51K	Buy	38 +17	+81%	+$1.31K	﹤0.01%	984
2021 Q2	$1.63K	Hold	21	–	–	﹤0.01%	1053
2021 Q1	$1.56K	Sell	21 -21	-50%	-$1.94K	﹤0.01%	1018
2020 Q4	$7.16K	Hold	42	–	–	﹤0.01%	860
2020 Q3	$5.9K	Hold	42	–	–	﹤0.01%	831
2020 Q2	$6.73K	Sell	42 -8	-16%	-$1.09K	﹤0.01%	820
2020 Q1	$4.89K	Buy	50 +2	+4%	+$229	﹤0.01%	814
2019 Q4	$6.19K	Buy	+48	New	+$4.84K	﹤0.01%	798

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

TD Private Client Wealth's SRPT Position: Q2 2026 in Review

TD Private Client Wealth held its Sarepta Therapeutics (SRPT) position steady in Q2 2026 at 33 shares worth $593. The position accounts for ﹤0.01% of the portfolio, ranked #1552.

TD Private Client Wealth first reported a position in SRPT in Q4 2019 and has held it in 13 quarters since. The position peaked at $7.16K in Q4 2020. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

TD Private Client Wealth held 33 shares of Sarepta Therapeutics worth $593 as of Q2 2026.
TD Private Client Wealth left its Sarepta Therapeutics share count unchanged in Q2 2026.
Sarepta Therapeutics made up ﹤0.01% of TD Private Client Wealth's portfolio in Q2 2026, its #1552 holding.
TD Private Client Wealth first reported a position in Sarepta Therapeutics in Q4 2019 and has held it in 13 quarters since.
TD Private Client Wealth's Sarepta Therapeutics position peaked at $7.16K in Q4 2020.
323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.